What SouthGenetics does

SouthGenetics is a Miami-based private diagnostic testing distributor founded in 2004 that operates as the regional channel for advanced genetic and molecular diagnostic tests across Latin America and the Caribbean. The company does not develop or own proprietary diagnostic technology; rather, it distributes and facilitates access to tests from approximately 15 international laboratory partners including LabCorp, BGI, BillionToOne, Veracyte, MDxHealth, Exact Sciences, Menarini, Castle Biosciences, SOPHiA GENETICS, LynxDx, Bioreference, Onkos, and Genomind. Its portfolio spans five medical specialties: gynecology (NIPT, Carrier Screening covering 500+ conditions, prenatal paternity testing, stem cell storage via NECBB), oncology (Oncotype Dx, SENTIS Pan-Cancer Discovery, CellSearch CTC, DecisionDx series, Mypath Melanoma, Tempus AI), urology (4Kscore, MyProstateScore 2.0, ConfirmMDx, Cxbladder, Genomic Prostate Score), endocrinology (Afirma, mirTHYpe), and psychiatry (Genomind Professional PGx). It also offers nutrigenetics, ImmunoCAP ISAC allergy testing, and Access One international health coverage.

The company's technology stack is essentially a curated, multi-vendor distribution layer rather than a unified platform. Each test is sourced from its originating laboratory partner and routed to patients and healthcare providers across 18+ countries through a direct-to-provider sales motion and an information-request-driven online lead capture flow. The primary operating entity, SouthGenetics Mexico, S.A. de C.V., is headquartered at the World Trade Center in Mexico City, with the Miami address functioning as the corporate domicile.

SouthGenetics operates a professional services revenue model: it monetizes by facilitating access to third-party diagnostic tests across multiple specialties in geographies where these tests are otherwise unavailable. No pricing is publicly disclosed, and customer engagement is consultative, initiated through website inquiry forms that route to country-specific follow-up. The company employs 11-50 people, has no disclosed funding, no parent company, no executive team listed in the input, and no patents or certifications in evidence.

Name

SouthGenetics

Legal name

SouthGenetics

Website

https://southgenetics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

SouthGenetics is a Miami-based diagnostic testing distributor, founded in 2004, that channels advanced genetic and molecular tests from 15+ international laboratories to healthcare providers and patients across 18+ Latin American and Caribbean countries, covering gynecology, oncology, urology, endocrinology, and psychiatry specialties.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Distribution

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostic testing
• Genetic testing distribution
• Prenatal screening services
• Oncology biomarker testing
• Diagnostic test distribution

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Diagnostic Testing Services: SouthGenetics provides advanced diagnostic tests across multiple medical specialties including prenatal testing, oncology, urology, endocrinology, and psychiatry. They distribute and facilitate access to molecular diagnostic tests from international laboratory partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

SouthGenetics curates and distributes advanced genetic and molecular diagnostic tests from leading international laboratories to patients and healthcare providers across Latin America and the Caribbean. Its portfolio spans non-invasive prenatal testing, carrier screening, prenatal paternity, liquid biopsies, oncology gene-expression profiling, urology biomarkers, endocrinology molecular tests, and pharmacogenomic testing, delivered via partnerships with LabCorp, BGI, BillionToOne, Veracyte, MDxHealth, Exact Sciences, Menarini, Castle Biosciences, and others.

Product overview

SouthGenetics is a diagnostic testing distributor and healthcare services company operating in Latin America and the Caribbean for 20 years. The company provides access to advanced genetic and molecular diagnostic tests through partnerships with major international laboratories. Their portfolio includes oncology tests (SENTIS Pan-Cancer Discovery, Oncotype Dx Breast, Cellsearch CTC, DecisionDx series, Mypath Melanoma, Tempus AI), urology tests (4Kscore, MyProstateScore 2.0, ConfirmMDx, Cxbladder, Genomic Prostate Score), endocrinology tests (Affirma, mirTHYpe), psychiatry services (Genomind Professional PGx), and gynecology services including Carrier Screening, NIPT, BabyPeek, and stem cell storage via NECBB. Additional services include prenatal paternity testing, nutrigenetics, allergy testing via ImmunoCAP ISAC, and Access One international health coverage. The company distributes tests from partners including BGI, Exact Sciences, Menarini, Castle Biosciences, Bioreference, Lynx Dx, MDxHealth, Veracyte, Onkos, Genomind, and collaborates with LabCorp, BillionToOne for prenatal testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive Prenatal Testing (NIPT) Advanced prenatal screening available from week 9 of pregnancy that assesses the risk of genetic disorders such as Down, Edwards, and Patau syndromes using a maternal blood sample. Offered in basic, intermediate, and advanced configurations through partnerships with LabCorp, BillionToOne, and BGI. Targeted at expectant parents and OB-GYNs across LATAM and the Caribbean.
• Carrier Screening Genetic analysis that detects whether an individual is a carrier of mutations associated with disorders including Cystic Fibrosis, Sickle Cell Anemia, Tay-Sachs disease, and Thalassemia, screening more than 500 genetic conditions. Targeted at couples planning families and OB-GYNs.
• Prenatal Paternity Testing Non-invasive prenatal paternity test available from week 7 of pregnancy using a maternal blood sample to compare fetal DNA with the alleged father's genetic profile. Targeted at expectant parents needing to establish biological paternity.
• Umbilical Cord Blood Stem Cell Storage (NECBB) Umbilical cord blood stem cell preservation services provided through partner New England Cord Blood Bank (NECBB), with over 50 years of experience and AABB, FDA, and CLIA accreditations. Targeted at expectant parents planning newborn stem cell preservation.
• Nutrigenetics Genetic analysis that studies how individual genetic variations influence responses to diet and nutrients, enabling personalized dietary recommendations. Targeted at individuals seeking personalized nutrition guidance.
• ImmunoCAP ISAC Allergy Testing Advanced immunological testing platform that identifies and quantifies IgE antibodies to multiple allergens simultaneously from a single blood sample. Targeted at allergists and patients with complex or poly-sensitized allergy profiles.
• Access One International Health Coverage International health coverage providing access to world-class medical centers for surgical interventions and complex treatments, including second medical opinions and emergency travel coverage. Targeted at patients in LATAM/Caribbean seeking global medical access.
• SENTIS Pan-Cancer Discovery Pan-cancer discovery panel from BGI for comprehensive cancer genomic profiling. Targeted at oncologists treating patients with various solid tumors across LATAM and Caribbean.
• Oncotype Dx Breast Genomic test for breast cancer patients from Exact Sciences that helps guide treatment decisions by analyzing the activity of specific genes for recurrence risk assessment. Targeted at breast cancer patients and oncologists in LATAM/Caribbean.
• CellSearch Circulating Tumor Cell (CTC) Circulating tumor cell test from Menarini for cancer detection and monitoring through a blood draw. Targeted at oncologists treating patients with metastatic breast, colorectal, or prostate cancer.
• DecisionDx-Melanoma Gene expression profile test from Castle Biosciences that provides prognostic information to guide treatment decisions for stage I-III cutaneous melanoma patients. Targeted at dermatologists, oncologists, and melanoma patients.
• DecisionDx-SCC Test from Castle Biosciences that identifies metastasis risk in high-risk squamous cell carcinoma patients and predicts which patients are most likely to benefit from adjuvant radiation therapy. Targeted at dermatologists and oncologists.
• DecisionDx-UM Test from Castle Biosciences that determines metastasis risk in uveal melanoma by identifying the molecular signature of an individual's tumor. Targeted at ocular oncologists and uveal melanoma patients.
• MyPath Melanoma Gene expression profile from Castle Biosciences designed to provide objective information to aid diagnosis and inform treatment decisions for patients with ambiguous melanocytic lesions. Targeted at dermatopathologists and dermatologists.
• Tempus AI Diagnostics AI-powered diagnostics platform from Tempus AI for accelerating therapeutic target discovery, predicting treatment effectiveness, identifying clinical trials, and diagnosing multiple diseases earlier. Targeted at oncologists and precision medicine programs.
• SOFIVA HRD Status Test from SOPHiA GENETICS for homologous recombination deficiency analysis used in selecting cancer treatment, particularly for PARP inhibitor eligibility. Targeted at oncologists and cancer genetics programs.
• 4Kscore Prostate cancer risk assessment test from Bioreference that measures four kallikrein biomarkers in blood to provide risk of aggressive prostate cancer. Targeted at urologists evaluating patients with elevated PSA.
• MyProstateScore 2.0 (MPS2) Prostate cancer screening test from LynxDx that evaluates genetic markers in urine to assess risk. Targeted at urologists screening men for prostate cancer.
• ConfirmMDx Tissue-based epigenetic test from MDxHealth that helps identify prostate cancer patients at risk for occult disease after a negative biopsy. Targeted at urologists managing patients with prior negative biopsies.
• Cxbladder Urine-based genomic test for bladder cancer detection and monitoring. Targeted at urologists evaluating hematuria and monitoring bladder cancer recurrence.
• Genomic Prostate Score (GPS) Genomic test from MDxHealth that provides prostate cancer risk stratification on biopsy tissue to help guide treatment decisions (active surveillance vs. intervention). Targeted at urologists managing newly diagnosed prostate cancer patients.
• SelectMDx Urine-based test from MDxHealth that measures gene expression to assess the likelihood of clinically significant prostate cancer prior to biopsy. Targeted at urologists making biopsy decisions.
• Afirma Xpression Atlas Thyroid cancer diagnostic test from Veracyte that analyzes gene expression and genomic variant patterns to characterize indeterminate thyroid nodules. Targeted at endocrinologists and thyroid surgeons.
• mirTHYpe MicroRNA-based thyroid test from Onkos used to characterize thyroid nodules and inform surgical decisions. Targeted at endocrinologists and head and neck surgeons.
• Genomind Professional PGx Pharmacogenomics test from Genomind that analyzes genetic variations to guide psychiatric medication selection and dosing. Targeted at psychiatrists managing patients with depression, anxiety, ADHD, and other mental health conditions.

Quantifiable outcome

• First to provide access to Non-Invasive Prenatal Testing (NIPT) in Latin America and the Caribbean
• +2 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

17 partnerships are on record, tiered core and minor.

• VeracytecoreTechnology or IntegrationVeracyte offers the Afirma (Xpression Atlas) test for thyroid nodule analysis, which SouthGenetics distributes in Latin America and the Caribbean as part of their endocrinology portfolio.
• NECBB (New England Cord Blood Bank)coreStrategic or Co-development PartnerPartnership for umbilical cord blood stem cell banking services with storage facilities in Boston. NECBB offers over 50 years of experience with AABB, FDA, and CLIA accreditations.
• MDxHealthcoreTechnology or IntegrationMDxHealth provides SelectMDx, ConfirmMDx, and Genomic Prostate Score tests for prostate cancer detection that SouthGenetics distributes in their urology portfolio.
• LabCorpcoreTechnology or IntegrationLabCorp is a major US laboratory partner providing prenatal testing services through SouthGenetics' global network for NIPT and other diagnostic tests.
• Exact SciencescoreTechnology or IntegrationExact Sciences provides Oncotype Dx Breast test for breast cancer recurrence assessment that SouthGenetics distributes in Latin America and the Caribbean.
• BillionToOnecoreTechnology or IntegrationBillionToOne is a US-based laboratory partner providing prenatal testing technologies included in SouthGenetics' global network for NIPT services.
• BGIcoreTechnology or IntegrationBGI provides SENTIS Pan-Cancer Discovery test and NIPT services. SouthGenetics includes BGI in their global laboratory network for prenatal testing with Hong Kong-based operations.
• MenarinicoreTechnology or IntegrationMenarini's CELLSEARCH Circulating Tumor Cell (CTC) test for cancer detection and monitoring is distributed by SouthGenetics in the oncology portfolio.
• Castle BiosciencescoreTechnology or IntegrationCastle Biosciences provides DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and Mypath Melanoma tests for skin cancer and uveal melanoma profiling distributed by SouthGenetics.
• Tempus AIcoreTechnology or IntegrationTempus AI provides AI-powered diagnostic capabilities for accelerating therapeutic target discovery, treatment effectiveness prediction, clinical trial identification, and early disease diagnosis.
• BioreferencecoreTechnology or IntegrationBioreference provides the 4Kscore test for prostate cancer risk assessment distributed by SouthGenetics in their urology portfolio.
• CxbladdercoreTechnology or IntegrationCxbladder provides urine-based bladder cancer detection tests distributed by SouthGenetics in their urology specialty area.
• OnkoscoreTechnology or IntegrationOnkos provides mirTHYpe thyroid cancer testing distributed by SouthGenetics in Latin America and the Caribbean.
• GenomindcoreTechnology or IntegrationGenomind provides the Professional PGx pharmacogenomic test for psychiatric medication guidance distributed by SouthGenetics in their psychiatry portfolio.
• Access OneminorStrategic or Co-development PartnerAccess One is an international health coverage provider partnered with SouthGenetics to offer exclusive access to their international health plan with worldwide medical coverage for surgical interventions and complex treatments.
• LynxDxcoreTechnology or IntegrationLynxDx provides MyProstateScore 2.0 (MPS2) test for prostate cancer screening distributed by SouthGenetics in their urology specialty.
• SOPHiA GENETICScoreTechnology or IntegrationSOPHiA GENETICS provides SOFIVA HRD Status test for homologous recombination deficiency analysis in cancer treatment selection.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat4 records

Customer concentration

• Xx.com/SouthGeneticsLA
• LinkedInlinkedin.com/company/south-genetics-inc-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SouthGenetics